PHARMACYCLICS GADOLITE MRI AGENT ENTERS PHASE III STUDIES
This article was originally published in The Gray Sheet
Executive Summary
PHARMACYCLICS GADOLITE MRI AGENT ENTERS PHASE III STUDIES for magnetic resonance imaging of the abdomen and pelvis, the firm announced Sept. 21. The multicenter trial, which is being conducted at 14 U.S. centers and one in Australia, will enroll 200 patients with "known or suspected abdominal and/or pelvic disease." To date, 15 patients have been enrolled in the trial; completion of the study is expected in early 1995, with a new drug application following in mid-1995.